ANGPT2 and diabetic retinopathy: That faricimab strongly down-regulates secretion of Ang-2 in vitro as well as in vivo, suggests an additional protective role of the antagonist in early and late stages of diabetic retinopathy, e.g., by counteracting Ang-2-caused loss of retinal pericytes or Ang-2-stimulated retinal neovascularization [37,47].